98%
921
2 minutes
20
BACKGROUND Uveal melanoma is the most common primary intraocular malignancy in adults, often diagnosed late in resource-limited settings. The diagnosis is made through a combination of clinical ophthalmologic examination, B-mode ultrasound, and histopathological study. This report details a case of a 67-year-old woman with progressive vision loss and ocular pain due to an inferomedial uveal melanoma to highlight therapeutic limitations from delayed diagnosis. CASE REPORT A 67-year-old woman presented with 3 years of progressive vision loss, ocular pain, and a pigmented inferomedial lesion in the right eye. Examination revealed light perception vision, intraocular pressure of 38 mmHg, and a conjunctival mass with feeder vessels. Ultrasound showed a large choroidal tumor occupying 70% of the vitreous. Enucleation confirmed a 19-mm-thick mixed-cell uveal melanoma (T4a per American Joint Committee on Cancer 8th edition) with scleral invasion. Postoperative computed tomography (CT) revealed no metastases. CONCLUSIONS Delayed presentation led to enucleation as the only viable treatment. This case underscores the critical need for public awareness, early detection, and effective referral systems of pigmented ocular lesions to preserve vision, expand therapeutic options, and ensure timely access to specialized care.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.12659/AJCR.947979 | DOI Listing |
Am J Case Rep
September 2025
Department of Ophthalmology, Brasília University Hospital, Brasília, DF, Brazil.
BACKGROUND Uveal melanoma is the most common primary intraocular malignancy in adults, often diagnosed late in resource-limited settings. The diagnosis is made through a combination of clinical ophthalmologic examination, B-mode ultrasound, and histopathological study. This report details a case of a 67-year-old woman with progressive vision loss and ocular pain due to an inferomedial uveal melanoma to highlight therapeutic limitations from delayed diagnosis.
View Article and Find Full Text PDFCureus
August 2025
Department of Ophthalmology, Hôpital Maisonneuve-Rosemont, Montreal, CAN.
Choroidal metastasis from occult cutaneous melanoma is rare and can masquerade as ocular inflammation. A 70‑year‑old man with sectoral anterior scleritis was found on multimodal imaging to have a solitary choroidal mass with mild periscleral fluid, prompting systemic evaluation that uncovered colonic polyps that, on histopathology, contained metastatic melanoma, a scalp primary, and widespread visceral, nodal, and intracranial metastases. Tumour cells stained HMB‑45, Melan‑A, and SOX10 positive, AE1/AE3 negative, and carried an NRAS‑Q61 mutation with wild‑type BRAF, confirming cutaneous origin.
View Article and Find Full Text PDFEur J Nucl Med Mol Imaging
September 2025
Department of Dermatology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
Purpose: Tebentafusp has emerged as the first systemic therapy to significantly prolong survival in treatment-naïve HLA-A*02:01 + patients with unresectable or metastatic uveal melanoma (mUM). Notably, a survival benefit has been observed even in the absence of radiographic response. This study aims to investigate the feasibility and prognostic value of artificial intelligence (AI)-assisted quantification and metabolic response assessment of [F]FDG long axial field-of-view (LAFOV) PET/CT in mUM patients undergoing tebentafusp therapy.
View Article and Find Full Text PDFRare melanoma subtypes, including acral, mucosal, and uveal melanomas, exhibit limited responses to immune checkpoint inhibitors (ICIs), yet the molecular mechanisms of immune resistance remain poorly defined. Here, we performed transcriptomic profiling of patient-derived xenografts (PDXs) and publicly available tumor datasets to systematically compare intratumoral gene expression across cutaneous and rare melanoma subtypes. We identified a convergent downregulation of innate immune pathogen sensing (IIPS) and type I interferon signaling pathways in rare melanomas compared to cutaneous, with lower expression also observed in anti-PD-1 non-responder tumors.
View Article and Find Full Text PDFOphthalmol Retina
September 2025
Ophthalmology Division, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.